Yang Jie, Ye Xiaowei, Liu Zhen, Sun Mengjia, Yu Shiyong, Lv Hailin, Wu Boji, Zhang Chen, Gu Wenzhu, He Jingyu, Wang Xuhong, Huang Lan
Institute of Cardiovascular Diseases of PLA, The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Department of Cardiology, The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Front Cardiovasc Med. 2023 Jul 25;10:1129144. doi: 10.3389/fcvm.2023.1129144. eCollection 2023.
Cardiorespiratory function influences exercise capacity and is an important determinant of high-altitude adaptation. Some studies have investigated the characteristics of changes in cardiorespiratory fitness during high-altitude acclimatization. However, studies on changes in cardiorespiratory fitness during high-altitude de-acclimatization are still lacking and have not yet been elucidated. Furthermore, few drugs have been studied to improve cardiorespiratory function during both processes. The Shigatse CARdiorespiratory Fitness (SCARF) study is a single-center, randomized, double-blind, placebo-control clinical trial to explore the effects of ubiquinol on cardiorespiratory fitness during high-altitude acclimatization and de-acclimatization in healthy adults. Participants will be randomly assigned 1:1 to ubiquinol 200 mg daily or a placebo for 14 days before departure until the end of data collection after return in 7 days. Cardiorespiratory fitness is the primary outcome, while acute mountain sickness and high-altitude de-acclimatization symptoms are secondary endpoints. In addition, laboratory measurements, including routine blood tests and serological measurements, will be performed. To the best of our knowledge, the SCARF study will be the first to reveal the changes in the cardiorespiratory fitness characteristics during high-altitude acclimatization and de-acclimatization. Furthermore, the results of this study will contribute to exploring whether ubiquinol supplementation could be beneficial for endurance exercise capacity at different altitudes and help improve adaptation to acute hypoxia and de-acclimatization. This study has been registered in the Chinese Clinical Trial Register (www.chictr.org.cn) as ChiCTR2200059900 and ChiCTR2200066328.
心肺功能影响运动能力，是高原适应的重要决定因素。一些研究调查了高原习服期间心肺适能变化的特征。然而，关于高原脱习服期间心肺适能变化的研究仍然缺乏，尚未得到阐明。此外，很少有药物在这两个过程中被研究用于改善心肺功能。日喀则心肺适能（SCARF）研究是一项单中心、随机、双盲、安慰剂对照的临床试验，旨在探讨泛醇对健康成年人在高原习服和脱习服期间心肺适能的影响。参与者将按1:1随机分配，在出发前14天每天服用200毫克泛醇或安慰剂，直至返回后7天数据收集结束。心肺适能是主要结局，而急性高原病和高原脱习服症状是次要终点。此外，还将进行包括血常规和血清学检测在内的实验室检测。据我们所知，SCARF研究将首次揭示高原习服和脱习服期间心肺适能特征的变化。此外，本研究结果将有助于探索补充泛醇是否对不同海拔的耐力运动能力有益，并有助于改善对急性缺氧和脱习服的适应。本研究已在中国临床试验注册中心（www.chictr.org.cn）注册，注册号为ChiCTR2200059900和ChiCTR2200066328。
